Welcome to the GARDASIL Access Program

Through the GARDASIL Access Program, Merck & Co., Inc. (Whitehouse Station, NJ, USA) has pledged to donate at least 3 million doses of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] for use in approved projects in eligible lowest income countries throughout the world.

The GARDASIL Access Program enables organizations and institutions in eligible lowest income countries to gain operational experience designing and implementing smaller scale human papillomavirus (HPV) vaccination projects, with the goal of supporting the development of successful child and adolescent immunization models.

Click here for more information on the GARDASIL Access Program

Latest News

  • The GARDASIL Access Program Welcomes New Participants in 2011
Following the July 2011 Advisory Board Meeting, a number of new applicants were recommended for participation in the program. Stay tuned to learn more about these newly approved participating organizations and institutions. 
  • Two New Sections of the GARDASIL Access Program Website Launches
To date, 876,800 doses of GARDASIL have shipped to 19 participants in 17 countries, enough to vaccinate more than 292,250 eligible girls. Click here to learn more about the participating organizations and institutions that have completed or are currently implementing HPV vaccination projects supported by the GARDASIL Access Program. Also, explore the Online Advocacy Kit, a new digital resource featuring downloadable materials and information from participants. 

 
name of img
Eligible Countries
Organizations and institutions in these countries are invited to submit an application form.
Read More
Newsletter
Newsletter, December 2010
The third GARDASIL® Access Program Newsletter is now available
Read More